Leadership
The Science History Institute is led by president and CEO David Cole, who works closely with the Board of Directors, Board of Advisors, Affiliates Council, and the Leadership Team to fulfill the Institute’s mission of expanding knowledge and sharing perspectives in the history of science.
Featured image: Detail of Board room at Rohm and Haas home office building, ca. 1964.
is the president and CEO of the Science History Institute. He is the former executive director of the Hagley Museum and Library, and has held positions at the Whitehead Institute for Biomedical Research and the Harvard Art Museums of Harvard University.
is the vice president of collections and programs and the Arnold Thackray Director of the Othmer Library at the Science History Institute. She is also the author of Lady Ranelagh: The Incomparable Life of Robert Boyle’s Sister.
is the Science History Institute’s chief financial officer. She is responsible for finance, accounting, facilities, and the Conference Center.
is the Institute’s director of communications and visitor experience. She has over a decade of experience designing engaging media and marketing campaigns, producing compelling stories, and sharing complex histories for nonprofits and the arts.
is the director of the Office of the President where she works with president and CEO David Cole to deepen the Institute’s individual and institutional relationships.
is the director of curatorial affairs and digital content. He is also coeditor of the Science History Institute’s collections blog.
Members of the Institute’s Board of Advisors help us reach others who understand and appreciate the impact of chemistry, chemical engineering, and the life sciences on society.
Ivan Amato
Author
Jacqueline K. Barton
California Institute of Technology
James C. Blair
Domain Associates
Joshua S. Boger
Vertex Pharmaceuticals
Katrine Bosley
DaCapo Brainscience
Robert J. Carpenter
Hydra Biosciences
Marc N. Casper
Thermo Fisher Scientific
Ron Cohen
Acorda Therapeutics
Pat N. Confalone
Confalone Consulting, LLC
Susan Desmond-Hellmann
Bill & Melinda Gates Foundation
Lawrence B. Evans
Rive Technology
Jay T. Flatley
Illumina
Christopher N. Garabedian
Xontogeny
Michael Grayson
Wu Guosheng
Tsinghua University
Rajiv L. Gupta
Avantor Performance Materials
David W. Haas
The William Penn Foundation
David F. Hale
Hale BioPharma Ventures
William A. Haseltine
ACCESS Health International
Roald Hoffmann
Cornell University
W. Richard Howe
Sally Smith Hughes
University of California, Berkeley
Stephen B. Jaffe
Shah Karim
SafeRock
Rachel K. King
GlycoMimetics, Inc.
Julius Lai
ArtShare
Robert S. Langer
Massachusetts Institute of Technology
Jeremy Levin
Ovid Therapeutics
Thomas B. Lewis
Chiral Technologies, retired
Maria L. Maccecchini
Annovis Bio
Magda Marquet
Ajinomoto Althea, Inc.
Joseph A. Miller, Jr.
Corning Corporation, retired
Scott W. Morrison
Ernst & Young, retired
Michael H. Ott
Polysciences, Inc.
Stelios Papadopoulos
Biogen
Sheng Peng
The Chemours Company
Adelene Perkins
Infinity Pharmaceuticals
Cecil B. Pickett
Zimmer Holdings, Inc.
Joseph Pilaro
Richard F. Pops
Alkermes
Philip Rakita
Roberto Rosenkranz
Roxro Pharma
Ivor Royston
Viracta Therapeutics
William J. Rutter
Synergenics, LLC
Phillip A. Sharp
Massachusetts Institute of Technology
Jay P. Siegel
Johnson & Johnson
Vincent F. Simmon
Genex
Peter H. Spitz
Chem Systems
Aya Tanaka
New York University
James Tarangelo
H. Holden Thorp
Washington University
Teddy Totimeh
University of Ghana Medical Centre
J. Craig Venter
J. Craig Venter Institute
Josef von Rickenbach
stet vision
Richard N. Zare
Stanford University